Wire Stories
-
566TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
Patients underwent BNCT using TAE Life Sciences� Neutron Beam System as part of Neuboron Medical Group�s NeuPex System at Xiamen Humanity Hospital...
-
547TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
Patients underwent BNCT using TAE Life Sciences� Neutron Beam System as part of Neuboron Medical Group�s NeuPex System at Xiamen Humanity Hospital...
-
378Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR� BRISBANE, Australia and EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a...
-
374Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR� BRISBANE, Australia and EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a...
-
385Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR� BRISBANE, Australia and EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a...
-
381VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and BRII-835 combination...
-
380VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and BRII-835 combination...
-
361VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and BRII-835 combination...
-
435Asahi Kasei Completes Second Plant for Ceolus� Microcrystalline Cellulose
NEW YORK & D�SSELDORF, Germany & TOKYO–(BUSINESS WIRE)–#asahikasei–Asahi Kasei, a diversified Japanese multinational company, has completed the construction of its second plant...
-
391Asahi Kasei Completes Second Plant for Ceolus� Microcrystalline Cellulose
NEW YORK & D�SSELDORF, Germany & TOKYO–(BUSINESS WIRE)–#asahikasei–Asahi Kasei, a diversified Japanese multinational company, has completed the construction of its second plant...
